Rossari Biotech Limited announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a consolidated revenue from operations of ₹581.7 crore for Q3 FY26, marking a 13% year-on-year increase. EBITDA stood at ₹68.9 crore, and PAT was ₹32.8 crore.

For the nine-month period ended December 31, 2025 (9M FY26), consolidated revenue from operations grew by 14% to ₹1,711.5 crore, with EBITDA at ₹208.7 crore and PAT at ₹103.2 crore.

The company highlighted steady growth in its core segments: Home, Personal Care and Performance Chemicals (HPPC) grew by 11% YoY, Textile Specialty Chemicals (TSC) by 18% YoY, and Animal Health and Nutrition (AHN) by 39% YoY during Q3 FY26. Exports also continued to support overall performance.

A significant development announced is the Board's in-principle approval to set up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA). This expansion, to be undertaken by its wholly-owned subsidiary Rossari International Limited, aims to enhance supply chain resilience and accelerate speed-to-market. The project progress is subject to customary evaluations and necessary regulatory approvals, with funding to be explored through equity, debt, internal accruals, or a combination.

Management commentary indicated that profitability was impacted by ongoing investments in capacity expansion, product development, and market-seeding initiatives, which are expected to strengthen long-term competitive positioning. The company remains confident that operating leverage, scale benefits, and an improving product mix will support margin improvement over time.

A conference call to discuss the Q3 FY26 earnings is scheduled for Monday, January 19, 2026, at 4:00 PM IST. The presentation for the results was shared on January 17, 2026.